Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Single-Center, Open-Label Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis

NCT03056989 is registered in ClinicalTrials.gov with Spyryx Biosciences, Inc. as lead sponsor.

NCT NCT03056989
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03056989 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Single-Center, Open-Label Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis
Lead sponsor
Spyryx Biosciences, Inc.
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2017
Completion date
August 2, 2017
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis